{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:18:33Z","timestamp":1789017513549,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Between October 2007 and July 2013, 183 Mayo Clinic patients (median age 65 years; 58% males) with high\/intermediate risk myelofibrosis (MF) were enrolled in consecutive phase 1\/2 JAK2 inhibitor (JAKi) clinical trials with momelotinib (<jats:italic>n<\/jats:italic>\u2009=\u200979), ruxolitinib (<jats:italic>n<\/jats:italic>\u2009=\u200950), fedratinib (<jats:italic>n<\/jats:italic>\u2009=\u200923) and BMS-911543 (<jats:italic>n<\/jats:italic>\u2009=\u200931). Using conventional criteria, the respective response rates for spleen and \u201ctransfusion-dependent anemia\u201d were 47%, 32%, 83%, 62% and 51%, 30%, 10%, 44%, respectively, favoring momelotinib for anemia response (<jats:italic>p<\/jats:italic>\u2009=\u20090.02) and fedratinib for spleen response (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). All study patients were followed to death or 2022, during which time 177 (97%) drug discontinuations, 27 (15%) leukemic transformations, and 22 (12%) allogeneic stem cell transplants (ASCT) were recorded. 5\/10-year survival rate for all 183 patients was 41%\/16% and not significantly different across the four drug cohorts (<jats:italic>p<\/jats:italic>\u2009=\u20090.33). Multivariable analysis of pre-treatment variables identified age &gt;65 years (HR 3.5), absence of type 1\/like <jats:italic>CALR<\/jats:italic> mutation (HR 2.8), baseline transfusion need (HR 2.1), and presence of <jats:italic>ASXL1<\/jats:italic>\/<jats:italic>SRSF2<\/jats:italic> mutation (HR 1.6) as risk factors for overall survival; subsequent HR-based modeling segregated three risk categories with 5\/10-year survival rates of 84%\/60%, 44%\/14%, and 21%\/5% (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). In addition, spleen (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) and anemia (<jats:italic>p<\/jats:italic>\u2009=\u20090.01) responses were independently associated with improved short-term survival while long-term survival was secured only by ASCT (5\/10-year survival rate 91%\/45% vs 47%\/19% in non-transplanted patients; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). The current retrospective study suggests the value of specific pre-treatment variables in identifying long-lived MF patients receiving JAKi and also confirms recent observations on the favorable impact of treatment response on short-term and of ASCT on long-term survival.<\/jats:p>","DOI":"10.1038\/s41408-022-00780-9","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T08:04:54Z","timestamp":1672819494000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-6172","authenticated-orcid":false,"given":"Naseema","family":"Gangat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2730-8593","authenticated-orcid":false,"given":"Kebede H.","family":"Begna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0824-3715","authenticated-orcid":false,"given":"Aref","family":"Al-Kali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5841-4105","authenticated-orcid":false,"given":"William","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-6302","authenticated-orcid":false,"given":"Mark","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-3821","authenticated-orcid":false,"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"780_CR1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ajh.26050","volume":"96","author":"A Tefferi","year":"2021","unstructured":"Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification, and management. Am J Hematol. 2021;96:145\u201362.","journal-title":"Am J Hematol"},{"key":"780_CR2","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al. Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis. N Engl J Med. 2010;363:1117\u201327.","journal-title":"N Engl J Med"},{"key":"780_CR3","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799\u2013807.","journal-title":"N Engl J Med"},{"key":"780_CR4","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787\u201398.","journal-title":"N Engl J Med"},{"key":"780_CR5","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/leu.2013.71","volume":"27","author":"A Pardanani","year":"2013","unstructured":"Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013;27:1322\u20137.","journal-title":"Leukemia."},{"key":"780_CR6","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/leu.2017.330","volume":"32","author":"A Pardanani","year":"2018","unstructured":"Pardanani A, Gotlib J, Roberts AW, Wadleigh M, Sirhan S, Kawashima J, et al. Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. Leukemia. 2018;32:1035\u20138.","journal-title":"Leukemia."},{"key":"780_CR7","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","volume":"35","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, et al. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor-naive patients with myelofibrosis. J Clin Oncol. 2017;35:3844\u201350.","journal-title":"J Clin Oncol"},{"key":"780_CR8","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","volume":"5","author":"CN Harrison","year":"2018","unstructured":"Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 2018;5:e73\u2013e81.","journal-title":"Lancet Haematol"},{"key":"780_CR9","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","volume":"29","author":"A Pardanani","year":"2011","unstructured":"Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011;29:789\u201396.","journal-title":"J Clin Oncol"},{"key":"780_CR10","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1182\/blood.V122.21.664.664","volume":"122","author":"A Pardanani","year":"2013","unstructured":"Pardanani A, Roberts AW, Seymour JF, Burbury K, Verstovsek S, Kantarjian HM, et al. BMS-911543, a selective JAK2 inhibitor: a multicenter phase 1\/2a study in myelofibrosis. Blood. 2013;122:664.","journal-title":"Blood."},{"key":"780_CR11","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","volume":"1","author":"A Pardanani","year":"2015","unstructured":"Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol. 2015;1:643\u201351.","journal-title":"JAMA Oncol"},{"key":"780_CR12","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood."},{"key":"780_CR13","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","volume":"122","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122:1395\u20138.","journal-title":"Blood."},{"key":"780_CR14","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/ajh.24978","volume":"93","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Nicolosi M, Mudireddy M, Szuber N, Finke CM, Lasho TL, et al. Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. Am J Hematol. 2018;93:348\u201355.","journal-title":"Am J Hematol"},{"key":"780_CR15","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29:392\u20137.","journal-title":"J Clin Oncol"},{"key":"780_CR16","doi-asserted-by":"publisher","first-page":"E433","DOI":"10.1002\/ajh.26714","volume":"97","author":"A Tefferi","year":"2022","unstructured":"Tefferi A, Pardanani A, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, et al. Momelotinib for myelofibrosis: 12-year survival data and retrospective comparison to ruxolitinib. Am J Hematol. 2022;97:E433\u2013e5.","journal-title":"Am J Hematol"},{"key":"780_CR17","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1182\/blood-2013-11-536557","volume":"123","author":"P Guglielmelli","year":"2014","unstructured":"Guglielmelli P, Biamonte F, Rotunno G, Artusi V, Artuso L, Bernardis I, et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood. 2014;123:2157\u201360.","journal-title":"Blood."},{"key":"780_CR18","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1182\/blood-2015-03-633404","volume":"126","author":"KP Patel","year":"2015","unstructured":"Patel KP, Newberry KJ, Luthra R, Jabbour E, Pierce S, Cortes J, et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015;126:790\u20137.","journal-title":"Blood."},{"key":"780_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0067-6","volume":"8","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Barraco D, Lasho TL, Shah S, Begna KH, Al-Kali A, et al. Momelotinib therapy for myelofibrosis: a 7-year follow-up. Blood Cancer J. 2018;8:29.","journal-title":"Blood Cancer J"},{"key":"780_CR20","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/leu.2014.306","volume":"29","author":"A Pardanani","year":"2015","unstructured":"Pardanani A, Abdelrahman RA, Finke C, Lasho TT, Begna KH, Al-Kali A, et al. Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis. Leukemia. 2015;29:741\u20134.","journal-title":"Leukemia."},{"key":"780_CR21","doi-asserted-by":"publisher","unstructured":"Gangat N, Begna KH, Al-Kali A, Hogan W, Litzow M, Pardanani A, et al. Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival. Am J Hematol. 2022. https:\/\/doi.org\/10.1002\/ajh.26778.","DOI":"10.1002\/ajh.26778"},{"key":"780_CR22","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","volume":"100","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015;100:1139\u201345.","journal-title":"Haematologica."},{"key":"780_CR23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1182\/bloodadvances.2021006006","volume":"6","author":"P Guglielmelli","year":"2022","unstructured":"Guglielmelli P, Ghirardi A, Carobbio A, Masciulli A, Maccari C, Mora B, et al. Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study. Blood Adv. 2022;6:373\u20135.","journal-title":"Blood Adv"},{"key":"780_CR24","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMc1109555","volume":"365","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med. 2011;365:1455\u20137.","journal-title":"N Engl J Med"},{"key":"780_CR25","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","volume":"36","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, et al. MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol. 2018;36:1769\u201370.","journal-title":"J Clin Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00780-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00780-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00780-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T08:08:45Z","timestamp":1672819725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00780-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["780"],"URL":"https:\/\/doi.org\/10.1038\/s41408-022-00780-9","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"assertion":[{"value":"14 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}